Knowledge mapping of biological disease-modifying anti-rheumatic drugs for axial spondyloarthritis: a bibliometric study

[1]  R. Landewé,et al.  Efficacy and safety of biological DMARDs: a systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis , 2022, Annals of the Rheumatic Diseases.

[2]  R. Landewé,et al.  Efficacy and safety of non-pharmacological and non-biological interventions: a systematic literature review informing the 2022 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis , 2022, Annals of the Rheumatic Diseases.

[3]  P. Machado,et al.  Comparing MRI and conventional radiography for the detection of structural changes indicative of axial spondyloarthritis in the ASAS cohort. , 2022, Rheumatology.

[4]  J Zhang,et al.  Knowledge Mapping of Necroptosis From 2012 to 2021: A Bibliometric Analysis , 2022, Frontiers in Immunology.

[5]  Bohan Jiang,et al.  Research on primary Sjögren’s syndrome in 2004–2021: a Web of Science-based cross-sectional bibliometric analysis , 2022, Rheumatology International.

[6]  Yumin Li,et al.  A Bibliometric and Knowledge-Map Analysis of CAR-T Cells From 2009 to 2021 , 2022, Frontiers in Immunology.

[7]  M. Ward,et al.  Predicting Probability of Response to Tumor Necrosis Factor Inhibitors for Individual Patients With Ankylosing Spondylitis , 2022, JAMA network open.

[8]  K. Hermann,et al.  MRI in axial spondyloarthritis: understanding an ‘ASAS-positive MRI’ and the ASAS classification criteria , 2022, Skeletal Radiology.

[9]  R. Scrivo,et al.  Effectiveness of non-medical switch from adalimumab bio-originator to SB5 biosimilar and from ABP501 adalimumab biosimilar to SB5 biosimilar in patients with chronic inflammatory arthropathies: a monocentric observational study. , 2022, Clinical and Experimental Rheumatology.

[10]  J. Gu,et al.  Quantification of Fat Metaplasia in the Sacroiliac Joints of Patients With Axial Spondyloarthritis by Chemical Shift-Encoded MRI: A Diagnostic Trial , 2022, Frontiers in Immunology.

[11]  Guixue Wang,et al.  Frontier and hot topics in electrochemiluminescence sensing technology based on CiteSpace bibliometric analysis. , 2021, Biosensors & bioelectronics.

[12]  Jan Christensen,et al.  Tapering of TNF inhibitors in axial spondyloarthritis in routine care-2-year clinical and MRI outcomes and predictors of successful tapering. , 2021, Rheumatology.

[13]  H. Won,et al.  Machine learning-based prediction model for responses of bDMARDs in patients with rheumatoid arthritis and ankylosing spondylitis , 2021, Arthritis Research & Therapy.

[14]  D. M. van der Heijde,et al.  Axial spondyloarthritis , 2021, Annals of the Rheumatic Diseases.

[15]  Weng Marc Lim,et al.  How to conduct a bibliometric analysis: An overview and guidelines , 2021 .

[16]  B. Cherqaoui,et al.  Axial spondyloarthritis: emerging drug targets , 2021, Expert opinion on therapeutic targets.

[17]  D. M. van der Heijde,et al.  Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study , 2021, Annals of the Rheumatic Diseases.

[18]  A. Boonen,et al.  A Phase III Randomized Study of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, for Active Ankylosing Spondylitis , 2021, The Journal of Rheumatology.

[19]  C. Ritchlin,et al.  Axial spondyloarthritis: new advances in diagnosis and management , 2021, BMJ.

[20]  E. Savarino,et al.  A propensity score-weighted comparison between adalimumab originator and its biosimilars, ABP501 and SB5, in inflammatory bowel disease: a multicenter Italian study , 2021, Therapeutic advances in gastroenterology.

[21]  OUP accepted manuscript , 2021, Rheumatology.

[22]  E. Koh,et al.  Machine learning to predict early TNF inhibitor users in patients with ankylosing spondylitis , 2020, Scientific Reports.

[23]  V. Navarro-Compán,et al.  Understanding the paradigm of non-radiographic axial spondyloarthritis , 2020, Clinical Rheumatology.

[24]  M. Dougados,et al.  Imaging Outcomes for Axial Spondyloarthritis and Sensitivity to Change: A Five‐Year Analysis of the DESIR Cohort , 2020, Arthritis care & research.

[25]  B. Dasgupta,et al.  Biologic agents and small-molecule inhibitors in systemic autoimmune conditions: an update. , 2020, Polish archives of internal medicine.

[26]  E. Lee,et al.  Comparison of the Effects of Secukinumab and Adalimumab Biosimilar on Radiographic Progression in Patients with Ankylosing Spondylitis: Design of a Randomized, Phase IIIb Study (SURPASS) , 2020, Clinical Drug Investigation.

[27]  M. Ward,et al.  2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis , 2019, Arthritis care & research.

[28]  L. Rogge,et al.  Anti-TNF Therapy in Spondyloarthritis and Related Diseases, Impact on the Immune System and Prediction of Treatment Responses , 2019, Front. Immunol..

[29]  M. Dougados,et al.  2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis , 2017, Annals of the rheumatic diseases.

[30]  D. M. van der Heijde,et al.  Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study , 2016, Annals of the rheumatic diseases.

[31]  C. Edwards,et al.  Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3) , 2016, Annals of the rheumatic diseases.

[32]  M. Dougados,et al.  Defining active sacroiliitis on MRI for classification of axial spondyloarthritis: update by the ASAS MRI working group , 2016, Annals of the rheumatic diseases.

[33]  G. Macfarlane,et al.  Global prevalence of ankylosing spondylitis. , 2014, Rheumatology.

[34]  J. Listing,et al.  Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS) , 2014, Annals of the rheumatic diseases.

[35]  M. Dougados,et al.  Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study , 2013, Annals of the rheumatic diseases.

[36]  M. Brown,et al.  Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1) , 2012, Annals of the rheumatic diseases.

[37]  M. Dougados,et al.  2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis , 2011, Annals of the rheumatic diseases.

[38]  M. Dougados,et al.  The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis , 2009, Annals of the rheumatic diseases.

[39]  M. Dougados,et al.  The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection , 2009, Annals of the rheumatic diseases.

[40]  D. M. van der Heijde,et al.  ASAS/EULAR recommendations for the management of ankylosing spondylitis: the patient version , 2008, Annals of the rheumatic diseases.

[41]  M. Dougados,et al.  Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. , 2006, Arthritis and rheumatism.

[42]  B. Dijkmans,et al.  Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). , 2005, Arthritis and rheumatism.

[43]  M. Dougados,et al.  Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. , 2003, Arthritis and rheumatism.

[44]  H. Zeidler,et al.  Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial , 2002, The Lancet.

[45]  A. Cats,et al.  Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. , 1984, Arthritis and rheumatism.